M Notification of a change(s) to the key information of a product approved by a stringent regulatory authority (SRA) (4 December 2015) DOCX
M Notification of an outcome of the national registration provided by the participating company to WHO-PQT, Annex 7 DOCX
M One-third of antimalarial medicines tested in six African countries fail to meet international quality standards (issued 25 February 2011) PDF
M Outline of the content of an annual report on the activities of a prequalified quality control laboratory (QCL) (4 June 2016) PDF
M Préqualification des laboratories de contrôle de qualité. Procédure d'evaluation de l'acceptabilité, de principe, des laboratoires de contrôle qualité à l'usage des institutions des Nations Unies PDF
M Principles for prioritizing dossiers within the WHO Prequalification Team: medicines (27 October 2011) PDF
M Public consultation on proposed financing model for WHO prequalification: summary of responses received
M Public consultation on proposed financing model for WHO prequalification: summary of responses received (issued 2 June 2015) PDF
M Q&A: Submission of applications for prequalification of magnesium sulfate injection (6 October 2014) PDF
M Quality assessment training, Denmark, 18‒21 May 2014: Active pharmaceutical ingredient assessment: impurities
M Quality assessment training, Denmark, 18‒21 May 2014: Bioequivalence: general considerations and Q&A
M Quality assessment training, Denmark, 18‒21 May 2014: Good manufacturing practice issues in quality assessment
M Quality Assurance of pharmaceuticals: a compendium of guidelines and related materials. Volume 2, Second updated edition, Good manufacturing practice and inspection PDF
M Quality Information Summary (QIS) of the Biotherapeutic Product (BTP) Approved by Stringent Regulatory Authority (SRA) - QIS-BTP-SRA DOCX
M Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Authority (SRA) (QIS-BTP-SRA) DOCX
M Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA) (QIS-BTP-SRA) DOCX
M Quality information summary (QIS) of the finished pharmaceutical product (FPP) approved by the reference stringent regulatory authority (SRA) (QIS-SRA) (28 October 2013) DOCX
M Recommendations on the content of a survey protocol: Survey of the quality of antimalarial medicines PDF
M Recommended comparator products: medicines for infections in newborns and young infants and childhood pneumonia PDF